UNITED STATES PATENT AND TRADEMARK OFFIC
BEFORE THE PATENT TRIAL AND APPEAL BOARD
LUPIN LTD. and LUPIN PHARMACEUTICALS INC.
Petitioners
v.
SENJU PHARMACEUTICAL CO., LTD.
Patent Owner
IPR2015-01871 Patent 8,129,431

OPPOSITION TO MOTION FOR JOINDER



## TABLE OF CONTENTS

I.	PRE	PRELIMINARY STATEMENT OF RELIEF REQUESTED1			
II.	BAC	BACKGROUND			
III.	THE BOARD SHOULD DENY JOINDER				5
	A.	Lupin bears the burden of establishing that joinder is appropriate.			
	B. Joinder is not appropriate here, because it would affect the Board's ability to timely complete its review and would unduly prejudice both InnoPharma and Senju.				7
		1.		vithout extension will affect the Board's ability complete the review	7
			a) Su	bstance	7
			b) Pro	ocedure	9
		2.	InnoPhar	joinder would unduly prejudice both rma and Senju, whereas Lupin would not be rejudiced if joinder was denied	13
IV	CON	JCI IIS	ION		15



# TABLE OF AUTHORITIES

Page(S
Patent Trial and Appeal Board Proceedings
Enzymotech Ltd. v. Neptune Techs., IPR2014-00556, Paper 19 (July 9, 2014)
Fifth Third Bank v. Leon Stambler, IPR2014-00244, Paper 4
InnoPharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2015-00903, Paper 2
Lupin Ltd. v. Senju Pharm. Co., Ltd., IPR2015-01097, Paper 1; IPR2015-01099, Paper 1; IPR2015-01105. Paper 1; IPR2015-01100, Paper 1
Metrics, Inc. v. Senju Pharm. Co., Ltd., IPR2014-01041, Paper 1
NetApp, Inc. v. PersonalWeb Techs., LLC, IPR2013-00319, Paper 18 (July 22, 2013)
Samsung Electronics Co., Ltd. & LG Electronics, Inc. v. Black Hills, LLC, IPR2014-00737, -00717, -00735, -00709, -00711, -00723, and -00740 joined by IPR2015-00334 to -00340 (Jan. 28, 2015)
Samsung Electronics Co. v. Arendi S.A.R.L., IPR2014-01144, Paper 111
SAP Am. Inc. v. Clouding IP, LLC, IPR2014-00306, Paper 13 (May 19, 2014)1
Sony Corp. of Am. v. Network-1 Sec. Solutions, Inc., IPR2013-00386, Paper 16 (July 29, 2013)
Teva Pharmaceuticals USA, Inc. v. VIIV Healthcare Co., IPR2015-00550. Paper 111



Unified Patents, Inc. v. Personalized Media Communications, LLC, IPR2015-00521, Paper 14	9, 10
Federal Statutes	
Hatch-Waxman Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984)	4
21 U.S.C. § 355(j)(2)(B)(ii)(I)	5
35 U.S.C. § 315(c)	5
35 U.S.C. § 316(a)(11)	1, 4
Regulations	
37 C.F.R. § 42.20(c)	6
37 C.F.R. § 42.122	5. 6



## I. PRELIMINARY STATEMENT OF RELIEF REQUESTED

Patent Owner Senju opposes the motion for joinder submitted by the Lupin Petitioners ("Lupin"), which presents new claim construction positions and new evidence, including a new declaration, that would require burdensome additional discovery and expert testimony, unduly prejudicing Senju and unduly burdening the Board. In the alternative, should the Board grant joinder, the Board should exercise its discretion under 35 U.S.C. § 316(a)(11) and extend the schedule in the joined proceedings to account for the additional complexity in these proceedings.

In December 2013, Lupin sent a Notice Letter informing Senju that Lupin had filed an Abbreviated New Drug Application ("ANDA") with a Paragraph IV Certification challenging Senju's U.S. Patent No. 8,129,431 ("the '431 patent"). The '431 patent covers the highly successful drug Prolensa® for treatment of pain and inflammation in patients undergoing cataract surgery. (EX2001.) Senju sued Lupin for infringement of the '431 patent on January 31, 2014, and the waiver of service of summons was filed on February 21, 2014. (EX2002; EX2003.)

Lupin then sat by and watched while other companies initiated IPRs challenging the '431 patent. Metrics, Inc. ("Metrics") initiated IPR2014-01041 challenging the '431 patent ("the Metrics IPR") on June 26, 2014. *Metrics, Inc. v. Senju Pharm. Co., Ltd.*, IPR2014-01041, Paper 1. A group of InnoPharma petitioners ("InnoPharma") then initiated IPR2015-00903 challenging the '431



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

